Jove
Visualize
Contact Us

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

1.5K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.5K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

1.5K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.5K
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

1.7K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.7K
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

2.7K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.7K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

2.7K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
2.7K
Hormones of the Adrenal Glands01:31

Hormones of the Adrenal Glands

4.6K
Adrenal hormones play a pivotal role in maintaining the body's electrolyte balance and orchestrating responses to stress, showcasing the intricate functions of the adrenal cortex and medulla.
The adrenal cortex, a powerhouse of hormone synthesis, generates over two dozen corticosteroid hormones. The zona glomerulosa produces mineralocorticoids, exemplified by aldosterone, influencing the electrolyte composition of body fluids. The synthesis of glucocorticoids such as cortisol and...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel 17 alpha-chloro-17 beta-sulfinyl steroids as specific inhibitors of sebaceous gland activity: potential antiacne agents.

Journal of medicinal chemistry·1983
Same author

The effects of a nonsteroid antiandrogen, flutamide, on sebaceous gland activity.

The Journal of investigative dermatology·1975
Same author

Biological aspects of antiandrogens.

Journal of steroid biochemistry·1975
Same author

Effects of a novel nonsteroidal antiandrogen on canine prostatic hyperplasia.

Investigative urology·1972
Same author

Permanent access to the peritoneal cavity in dogs: a method for massive leukocyte withdrawal.

American journal of veterinary research·1970
Same author

Biological properties of three ovulation inducers, stilboestrol, clomiphene and F 6066.

Acta endocrinologica·1968
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jan 19, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.4K

Antiandrogens.

R O Neri

    Advances in Sex Hormone Research
    |January 1, 1976
    PubMed
    Summary

    Researchers are developing antiandrogens to block androgen action through various mechanisms. While effective in treating conditions like prostate hyperplasia, further research is needed for more potent agents with fewer side effects.

    Area of Science:

    • Endocrinology
    • Pharmacology

    Background:

    • Antiandrogens are crucial for managing androgen-dependent conditions.
    • Existing antiandrogens, both steroidal and nonsteroidal, often exhibit off-target effects, complicating mechanism elucidation.
    • Understanding androgen action at the molecular level is vital for therapeutic advancements.

    Purpose of the Study:

    • To review the mechanisms by which antiandrogens exert their effects.
    • To highlight the therapeutic applications and limitations of current antiandrogens.
    • To emphasize the ongoing need for novel antiandrogen development.

    Main Methods:

    • Review of existing literature on antiandrogen synthesis and biological assays.
    • Analysis of different mechanisms for blocking androgen action.

    More Related Videos

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    13.7K
    Murine Prostate Micro-dissection and Surgical Castration
    08:49

    Murine Prostate Micro-dissection and Surgical Castration

    Published on: May 11, 2016

    47.5K

    Related Experiment Videos

    Last Updated: Jan 19, 2026

    Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
    06:24

    Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

    Published on: January 10, 2025

    1.4K
    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    13.7K
    Murine Prostate Micro-dissection and Surgical Castration
    08:49

    Murine Prostate Micro-dissection and Surgical Castration

    Published on: May 11, 2016

    47.5K
  • Evaluation of clinical effectiveness in various conditions.
  • Main Results:

    • Antiandrogens can block androgen action via gonadotropin inhibition, interference with steroid biosynthesis, protein synthesis inhibition, or receptor site competition.
    • Several antiandrogens are clinically effective for prostatic hyperplasias, hirsutism, and acne.
    • Many compounds possess additional biological activities, complicating precise mechanistic studies.

    Conclusions:

    • Antiandrogens are valuable therapeutic agents and research tools for studying androgen action.
    • Despite clinical successes, the development of more potent antiandrogens with improved safety profiles is essential.
    • Continued research is necessary to refine antiandrogen therapies and understand their molecular mechanisms.